An immune profile of tumor pd‐l1 expression plus cd4 or cd8 t cell infiltrations correlated with treatment efficacy of pd‐1 blockade antibodies in nsclc patients

patients using Targeted therapy Results: In total, 30 patients were analyzed (12 males, 18 females; median age 58.7 11.17 with 33.3% of them were smokers and 13.3% of them were passive smokers). Tissue biopsies were obtained by pleural biopsy (63.3%), endobronchial biopsy (16.6%), and CT/Ultrasound guided biopsy (23.3%). All of them had EGFR mutations. 19 of them received TKI as the first line chemotherapy where else 6 of them received cisplatin based chemotherapy. Progression free survival (PFS) in the group received TKI were significantly longer (8.4 months) than group which received cisplatin based chemo (6.8 months). Median target lesions, which treated by TKI’s reduced from 48 mm (pretreatment) to 32.5 mm (post treatment. Non target lesions reduced to 15 mm (post treatment) from 23 mm (pretreatment). Many of them develop side effects of skin (46.7%). Conclusion: There were clinical benefits for patients who received TKI as first line therapy in EGFR mutation patients.